Robert W. Baird downgraded shares of Onyx Pharmaceuticals (NASDAQ:ONXX) from an outperform rating to a neutral rating in a research note released on Monday morning, TheFlyOnTheWall.com reports. They currently have $129.00 target price on the stock.
Onyx Pharmaceuticals (NASDAQ:ONXX) traded up 0.26% on Monday, hitting $132.03. Onyx Pharmaceuticals has a 1-year low of $66.37 and a 1-year high of $136.87. The stock’s 50-day moving average is currently $113.. The company’s market cap is $9.604 billion.
A number of other firms have also recently commented on ONXX. Analysts at Deutsche Bank downgraded shares of Onyx Pharmaceuticals from a buy rating to a hold rating in a research note to investors on Monday, July 22nd. They now have a $140.00 price target on the stock, up previously from $110.00. Separately, analysts at UBS AG raised their price target on shares of Onyx Pharmaceuticals from $110.00 to $150.00 in a research note to investors on Monday, July 15th. Finally, analysts at JMP Securities downgraded shares of Onyx Pharmaceuticals from an outperform rating to a market perform rating in a research note to investors on Monday, July 15th.
Seven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $119.69.
In other Onyx Pharmaceuticals news, CFO Matthew K. Fust dumped 6,043 shares of the stock in a transaction that occured on Friday, July 26th. The shares were sold at an average price of $130.50, for a total transaction of $788,611.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Onyx Pharmaceuticals, Inc (NASDAQ:ONXX) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.